Protective antibiotic titres for measles, mumps and rubella in children and adolescents with chronic kidney disease
Not Applicable
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecified
- Registration Number
- CTRI/2019/06/019873
- Lead Sponsor
- Maulana Azad medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All children and adolescents aged between 2-19 years with chronic kidney disease who have received atleast one dose of measles containing vaccine.
Exclusion Criteria
children and adolescents having received immunosuppressive drugs, unimmunized children with chronic kidney disease.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie reduced MMR seroprotection in CKD N189 patients compared to healthy controls?
How do MMR antibody titers in CKD N189 patients compare to standard vaccination thresholds for seroprotection?
Which immune biomarkers correlate with durable MMR seroprotection in pediatric CKD populations?
What adverse events are associated with MMR vaccination in children with CKD stages 3-5 (N189) and how are they managed?
Are alternative vaccination strategies (e.g., higher-dose MMR) being evaluated for CKD N189 patients with suboptimal antibody titers?